RIPK3 and medical procedure: In CRC, although the tumor-suppressing effects of RIPK3 and RIPK1 have been discovered (Moriwaki et al., 2015), RIPK3-mediated inflammation was reported to promote intestinal tumors by inducing an immune-suppressive tumor microenvironment (TME) (Jayakumar and Bothwell, 2019; Liu et al., 2019), and RIPK1 has been shown to interact with mitochondrial Ca2+ uniporter (MCU) to promote colorectal oncogenesis (Zeng et al., 2018).